The use of tryptase and tryptase genotyping assessments is revolutionizing the screening, diagnosis, and management of systemic mastocytosis (SM). Here’s a comprehensive review and update. A Serious ...

Patients with indolent mastocytosis may express concern about anaphylaxis or milder reactions to various substances, but Dr. Aaron T. Gerds, of Cleveland Clinic, reminds them that "you can't go into a ...

Credit: Blueprint Medicines. The approval was based on data from the double-blind, placebo-controlled PIONEER trial. The Food and Drug Administration (FDA) has approved Ayvakit ® (avapritinib) for the ...

Please provide your email address to receive an email when new articles are posted on . "Ayvakit is the first and only medicine approved by the FDA to treat indolent systemic mastocytosis, marking a ...

Credit: Getty Images. The sNDA is supported by data from the phase 2 PIONEER trial that evaluated the efficacy and safety of avapritinib in patients with indolent systemic mastocytosis. The Food and ...

-- For the first time, the estimated 40,000 patients with indolent SM in the EU 1,2* would have a medicine that treats the primary disease driver 3,4 -- -- Opinion based on the positive PIONEER trial, ...

In the complex world of rare diseases, even small advances in understanding can make a profound difference in patients’ lives. Medscape Live is bringing back-to-back educational programs to San Diego ...

CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ -- Blueprint Medicines Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT ® (avapritinib) for the treatment ...

CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group, has ...

CAMBRIDGE, Mass., Feb. 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced detailed results from the PIONEER trial of AYVAKIT ® (avapritinib) in patients with ...

CAMBRIDGE, Mass., Feb. 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® ...